Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...

An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...

Yearly doses could reduce barriers people face to taking preventative HIV medication, researchers said. An annual jab to ...

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...

A yearly injection to protect against HIV is safe and shows promise as a prevention method with long-lasting effects, according to the results of a c ...